The first is sweetness and texture
GLP-1 agonists reduce hyperglycemia by enhancing insulin secretion and inhibiting the production of glucagon, and they delay gastric emptying and reduce appetite (127)
In STEP 1 involving semaglutide, there was a reduction in body mass index of 5.5 kg/m2, with corresponding reductions in systolic blood pressure of 6.2 mmHg along with reductions in total and LDL-cholesterol of 3% each, increases in HDL-cholesterol of 5%, and reductions in triglycerides of 22% [9]
CJC-1295 is a GHRH analog (it tells the pituitary to make GH), while ipamorelin is a growth-hormone secretagogue (it triggers the release of stored GH)
A major issue is that standardization is still lacking
The delivery of pharmaceutical compounds to increase NO signaling in diseased skeletal muscle is feasible and candidate drugs are currently being investigated [72]